About Radius Health (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDUS
CUSIPN/A
Phone617-551-4000
Debt
Debt-to-Equity Ratio0.69%
Current Ratio5.04%
Quick Ratio4.96%
Price-To-Earnings
Trailing P/E Ratio-5.68
Forward P/E Ratio-6.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.11 million
Price / Sales67.48
Cash FlowN/A
Price / CashN/A
Book Value$5.43 per share
Price / Book6.07
Profitability
EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net MarginsN/A
Return on Equity-99.97%
Return on Assets-67.64%
Miscellaneous
Employees561
Outstanding Shares45,250,000
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health (NASDAQ:RDUS) announced its earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by $0.16. The biopharmaceutical company earned $7.66 million during the quarter, compared to analyst estimates of $7.37 million. The company's quarterly revenue was up 666.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.22) earnings per share. View Radius Health's Earnings History.
What price target have analysts set for RDUS?
11 Wall Street analysts have issued 12-month price targets for Radius Health's shares. Their predictions range from $24.00 to $85.00. On average, they expect Radius Health's stock price to reach $52.10 in the next year. View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months." (1/8/2018)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
- 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include Ionis Pharmaceuticals (IONS), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), United Therapeutics (UTHR), Galápagos (GLPG), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC) and Ligand Pharmaceuticals (LGND).
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Kurt C. Graves, Independent Chairman of the Board (Age 49)
- Jesper Hoiland, President, Chief Executive Officer, Director (Age 56)
- Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer (Age 45)
- Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer (Age 50)
- Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary (Age 52)
- Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 63)
- Gregory Williams Ph.D., Chief Development Officer (Age 58)
- Willard H. Dere M.D., Independent Director (Age 63)
- Catherine J. Friedman, Independent Director (Age 56)
- Jean-Pierre Garnier Ph.D., Independent Director (Age 69)
Has Radius Health been receiving favorable news coverage?
News coverage about RDUS stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Radius Health earned a news impact score of 0.13 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.01 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $32.97.
How big of a company is Radius Health?
Radius Health has a market capitalization of $1.48 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (RDUS)
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Radius Health (NASDAQ:RDUS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Radius Health in the last 12 months. Their average twelve-month price target is $52.10, suggesting that the stock has a possible upside of 58.02%. The high price target for RDUS is $85.00 and the low price target for RDUS is $24.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.64 | 2.60 | 2.56 | 2.63 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $52.10 | $52.00 | $49.8571 | $52.1667 |
| Price Target Upside: | 58.02% upside | 53.71% upside | 31.13% upside | 35.57% upside |
Radius Health (NASDAQ:RDUS) Consensus Price Target History
Radius Health (NASDAQ:RDUS) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Radius Health (NASDAQ:RDUS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Radius Health (NASDAQ RDUS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.00%
Radius Health (NASDAQ RDUS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/19/2018 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $33.80 | $1,352,000.00 | 6,050,913 |  |
| 4/5/2018 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.58 | $1,829,000.00 | 5,903,799 | |
| 3/2/2018 | Growth N V Biotech | Major Shareholder | Buy | 80,000 | $32.52 | $2,601,600.00 | 5,853,799 | |
| 2/9/2018 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $34.38 | $2,578,500.00 | 5,773,799 | |
| 11/14/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $26.25 | $1,312,500.00 | 5,698,799 | |
| 11/10/2017 | Brent Hatzis-Schoch | VP | Buy | 1,778 | $28.09 | $49,944.02 | 2,278 | |
| 11/7/2017 | Jesper Hoiland | Insider | Buy | 6,800 | $29.04 | $197,472.00 | 12,900 | |
| 11/3/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $29.15 | $1,457,500.00 | 5,648,799 | |
| 10/25/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $32.85 | $1,642,500.00 | 5,548,799 | |
| 9/15/2017 | Jesper Hoiland | Insider | Buy | 6,100 | $32.72 | $199,592.00 | 6,100 | |
| 9/14/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $33.45 | $5,017,500.00 | 5,448,799 | |
| 9/14/2017 | Jose Carmona | CFO | Buy | 3,000 | $32.83 | $98,490.00 | 3,000 | |
| 9/12/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.42 | $1,771,000.00 | 5,348,799 | |
| 9/5/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.75 | $1,837,500.00 | 5,298,799 | |
| 8/16/2017 | Growth N V Biotech | Major Shareholder | Buy | 60,000 | $35.98 | $2,158,800.00 | 5,248,799 | |
| 8/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $34.97 | $5,245,500.00 | 5,113,799 | |
| 5/30/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $34.21 | $1,368,400.00 | 5,038,799 | |
| 5/25/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $36.25 | $1,450,000.00 | 4,998,799 | |
| 5/18/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $34.41 | $1,720,500.00 | 4,958,799 | |
| 5/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $33.44 | $1,170,400.00 | 4,890,799 | |
| 5/12/2017 | Growth N V Biotech | Major Shareholder | Buy | 15,000 | $34.00 | $510,000.00 | 4,873,799 | |
| 5/9/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.93 | $1,796,500.00 | 4,858,799 | |
| 5/8/2017 | Growth N V Biotech | Major Shareholder | Buy | 43,400 | $35.57 | $1,543,738.00 | 4,785,999 | |
| 5/2/2017 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $33.91 | $2,543,250.00 | 4,765,399 | |
| 5/1/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $35.39 | $5,308,500.00 | 4,690,399 | |
| 3/21/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.83 | $1,791,500.00 | 4,540,399 | |
| 3/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 30,000 | $38.41 | $1,152,300.00 | 4,490,399 | |
| 3/15/2017 | Growth N V Biotech | Major Shareholder | Buy | 61,721 | $39.97 | $2,466,988.37 | 4,415,930 | |
| 3/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 38,279 | $39.17 | $1,499,388.43 | 4,398,678 | |
| 1/22/2016 | Growth N V Biotech | Major Shareholder | Buy | 38,259 | $31.67 | $1,211,662.53 | 4,360,399 | |
| 1/13/2016 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $39.90 | $1,995,000.00 | 4,322,140 | |
| 11/12/2015 | Gary Hattersley | insider | Sell | 5,683 | $75.00 | $426,225.00 | | |
| 11/3/2015 | Gary Hattersley | insider | Sell | 13,333 | $70.00 | $933,310.00 | | |
| 10/23/2015 | Gary Hattersley | insider | Sell | 11,302 | $65.00 | $734,630.00 | | |
| 10/21/2015 | Gary Hattersley | insider | Sell | 1,501 | $65.36 | $98,105.36 | | |
| 10/21/2015 | Rob Ward | CEO | Sell | 50,000 | $61.99 | $3,099,500.00 | | |
| 8/21/2015 | Growth N. V. Biotech | major shareholder | Buy | 100,000 | $64.00 | $6,400,000.00 | 4,272,140 | |
| 8/17/2015 | Kurt Graves | Director | Sell | 22,694 | $70.00 | $1,588,580.00 | | |
| 7/6/2015 | Kurt Graves | Director | Sell | 25,000 | $69.48 | $1,737,000.00 | | |
| 6/18/2015 | Kurt Graves | Director | Sell | 25,000 | $55.05 | $1,376,250.00 | | |
| 5/1/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.46 | $1,823,000.00 | | |
| 4/29/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.23 | $1,811,500.00 | | |
| 4/28/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.59 | $1,829,500.00 | | |
| 4/27/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $38.38 | $1,919,000.00 | | |
| 3/6/2015 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $47.08 | $3,531,000.00 | | |
| 2/25/2015 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $45.74 | $1,600,900.00 | | |
| 6/11/2014 | Morana Jovan-Embiricos | Director | Buy | 587,500 | $8.00 | $4,700,000.00 | | |
| 6/6/2014 | Growth N V Biotech | Major Shareholder | Buy | 1,000,000 | $8.00 | $8,000,000.00 | | |
(Data available from 1/1/2013 forward)
Radius Health (NASDAQ RDUS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10 ...
globenewswire.com - April 26 at 5:02 PM |
 | Radius Health (RDUS) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 26 at 1:32 PM |
 | Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018
finance.yahoo.com - April 24 at 8:39 AM |
| Insider Buying: Radius Health (RDUS) Major Shareholder Acquires 40,000 Shares of Stock
www.americanbankingnews.com - April 23 at 4:24 PM |
| Radius Health (RDUS) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM |
| Radius Health Target of Unusually High Options Trading (RDUS)
www.americanbankingnews.com - April 19 at 8:00 AM |
| Stock Traders Buy High Volume of Call Options on Radius Health (RDUS)
www.americanbankingnews.com - April 19 at 8:00 AM |
| Radius Health (RDUS) PT Set at $65.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 17 at 10:21 PM |
| Radius Health (RDUS) Given a $85.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 17 at 10:21 PM |
| Radius Health (RDUS) Expected to Post Quarterly Sales of $13.81 Million
www.americanbankingnews.com - April 17 at 4:59 AM |
| Cantor Fitzgerald Reiterates $58.00 Price Target for Radius Health (RDUS)
www.americanbankingnews.com - April 16 at 10:22 PM |
| Canaccord Genuity Reiterates "$85.00" Price Target for Radius Health (RDUS)
www.americanbankingnews.com - April 15 at 8:37 AM |
| Analysts Anticipate Radius Health (RDUS) to Post -$1.40 EPS
www.americanbankingnews.com - April 15 at 3:11 AM |
| Zacks Investment Research Upgrades Radius Health (RDUS) to Hold
www.americanbankingnews.com - April 12 at 7:25 PM |
| Growth N. V. Biotech Acquires 50,000 Shares of Radius Health (RDUS) Stock
www.americanbankingnews.com - April 9 at 4:11 PM |
| Q1 2018 EPS Estimates for Radius Health Decreased by Analyst (RDUS)
www.americanbankingnews.com - April 9 at 1:19 AM |
 | UPDATE: Leerink Partners Starts Radius Health (RDUS) at Outperform
www.streetinsider.com - April 7 at 8:58 AM |
| Radius Health Inc (RDUS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 9:12 AM |
| Radius Health (RDUS) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 12:32 AM |
| Radius Health (RDUS) Down 4.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 2 at 9:06 AM |
 | Is Radius Health Worth Your Time?
seekingalpha.com - March 31 at 8:38 AM |
| Analysts Expect Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million
www.americanbankingnews.com - March 31 at 4:16 AM |
| Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis
finance.yahoo.com - March 30 at 5:11 PM |
| Radius Health (RDUS) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 29 at 3:36 PM |
| Radius Health (RDUS) Now Covered by Leerink Swann
www.americanbankingnews.com - March 29 at 8:36 AM |
| Analysts Anticipate Radius Health Inc (RDUS) Will Announce Earnings of -$1.42 Per Share
www.americanbankingnews.com - March 29 at 5:17 AM |
| Radius Health (RDUS) Given "Hold" Rating at Citigroup
www.americanbankingnews.com - March 27 at 10:27 AM |
| Radius Health Down on Negative CHMP Opinion for Lead Drug
finance.yahoo.com - March 23 at 5:18 PM |
| Morgan Stanley Lowers Radius Health (RDUS) Price Target to $59.00
www.americanbankingnews.com - March 23 at 4:34 PM |
| Waltham’s Radius Health says osteoporosis drug rejected in Europe
finance.yahoo.com - March 22 at 5:16 PM |
| Radius Health (RDUS) Given a $58.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 22 at 11:52 AM |
 | Quotidian Technical Highlights on Selected Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health ... - PR Newswire (press release)
www.prnewswire.com - March 20 at 5:00 PM |
 | Radius Health Announces Positive Data on Lead Drug Tymlos - Nasdaq
www.nasdaq.com - March 20 at 5:00 PM |
| Radius Health (RDUS) Announces Positive Data for ACTIVExtend BMD Responder Analysis for TYMLOS ... - StreetInsider.com
www.streetinsider.com - March 19 at 8:48 AM |
| Radius Health Presents Positive Data From ACTIVExtend BMD Responder Analysis - Nasdaq
www.nasdaq.com - March 18 at 6:00 PM |
| Commit To Purchase Radius Health At $22.50, Earn 8.7 ... - Nasdaq - Nasdaq
www.nasdaq.com - March 16 at 8:49 AM |
| Zacks: Brokerages Anticipate Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million
www.americanbankingnews.com - March 14 at 8:38 AM |
| Radius Health (RDUS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 12 at 6:15 PM |
| Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection
finance.yahoo.com - March 12 at 6:15 PM |
| Radius Health Inc (RDUS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 7:36 AM |
| Radius Health Inc (RDUS) Major Shareholder Growth N. V. Biotech Purchases 80,000 Shares
www.americanbankingnews.com - March 6 at 6:14 PM |
| Radius Health to Present at the Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:38 AM |
| Prosight Management LP Takes $3.50 Million Position in Radius Health Inc (RDUS)
www.americanbankingnews.com - March 5 at 2:55 PM |
| Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses - Nasdaq
www.nasdaq.com - March 3 at 8:38 AM |
| Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 8:38 AM |
| Radius Health (RDUS) Price Target Raised to $61.00 at Morgan Stanley
www.americanbankingnews.com - March 2 at 10:03 PM |
 | Here's Why Radius Health Dropped as Much as 14.7% Today
www.msn.com - March 2 at 5:47 PM |
| Here's Why Radius Health Dropped as Much as 14.7% Today
finance.yahoo.com - March 2 at 5:47 PM |
| Radius Health (RDUS) Announces Quarterly Earnings Results, Misses Estimates By $0.16 EPS
www.americanbankingnews.com - March 1 at 9:12 PM |
| Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update
finance.yahoo.com - March 1 at 5:32 PM |
Radius Health (NASDAQ:RDUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Radius Health (NASDAQ:RDUS) Income Statement, Balance Sheet and Cash Flow Statement
Radius Health (NASDAQ RDUS) Stock Chart for Thursday, April, 26, 2018
Loading chart…
